BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

18 articles for P Jeffrey

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo properties.EBI
Glaxosmithkline
Design and synthesis of novel 2,3-dihydro-1H-isoindoles with high affinity and selectivity for the dopamine D3 receptor.EBI
Smithkline Beecham Pharmaceuticals
1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor.EBI
Glaxosmithkline
Novel 2,3,4,5-tetrahydro-1H-3-benzazepines with high affinity and selectivity for the dopamine D3 receptor.EBI
Smithkline Beecham Pharmaceuticals
Novel 1,2,3,4-tetrahydroisoquinolines with high affinity and selectivity for the dopamine D3 receptor.EBI
Smithkline Beecham Pharmaceuticals
Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.EBI
Glaxosmithkline
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.EBI
Glaxosmithkline
Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134).EBI
Smithkline Beecham Pharmaceuticals
Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat.EBI
Smithkline Beecham Pharmaceuticals
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.EBI
University of Cambridge
Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer.EBI
Bicycletx
Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology.EBI
Bicycle Therapeutics
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.EBI
University of Oxford
Discovery of potent and stable conformationally constrained analogues of the MCH R1 antagonist SB-568849.EBI
Glaxosmithkline
SAR of biphenyl carboxamide ligands of the human melanin-concentrating hormone receptor 1 (MCH R1): discovery of antagonist SB-568849.EBI
Glaxosmithkline
Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.EBI
Glaxosmithkline Pharmaceuticals
Rho kinase inhibitors and methods of useBDB
H. Lee Moffitt Cancer Center and Research Institute
Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-binding, more isoform-selective inhibitors.BDB
Cnr